Back to Newsroom

PTC Therapeutics Expands Global Presence in Support of Translarna™ Launch in Duchenne Muscular Dystrophy

SOUTH PLAINFIELD, N.J., Sept. 17, 2014 /PRNewswire/ — PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced the expansion of its global presence with the addition of key executives to leadership positions in PTC’s global commercial team and the establishment of its international headquarters in Dublin, Ireland. Significant pre-launch activities are well underway as PTC prepares for the commercial launch of Translarna™ (ataluren) in the European Union. In August of this year, Translarna received approval from the European Medicines Agency for the treatment of nonsense mutation Duchenne muscular dystrophy (nmDMD).

Click here to read more